title: [Nasal septum perforation and bevacizumab].
abstract: A 52-year-old woman, with a metastatic breast cancer, presented with a nasal septum perforation while receiving a treatment combining paclitaxel and bevacizumab. This is the fifth reported case of nasal septum perforation probably related to an anti-angiogenic therapy. A literature review and a discussion concerning the different causes of nasal septum perforation were performed.
authors.affiliation: Service d'oncologie médicale, hôpital Saint-Antoine, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France. leila.bengrine-lefevre@sat.aphp.fr
authors.forename: L
authors.initials: L
authors.lastname: Bengrine-Lefevre
authors.forename: P
authors.initials: P
authors.lastname: Afchain
authors.forename: B
authors.initials: B
authors.lastname: Chibaudel
authors.forename: H
authors.initials: H
authors.lastname: Gervais
authors.forename: C
authors.initials: C
authors.lastname: Tournigand
authors.forename: A
authors.initials: A
authors.lastname: De Gramont
authors.forename: C
authors.initials: C
authors.lastname: Louvet
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy / Q000556:secondary; D005260:Female; D006801:Humans; D008875:Middle Aged; D009300:Nasal Septum / Q000187:drug effects* / Q000473:pathology*; D009668:Nose Diseases / Q000139:chemically induced* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017239:Paclitaxel